Cadisegliatin (TTP399) is a liver-selective glucokinase activator. It is being developed by VTV Therapeutics for treatment of type 2 diabetes or type 1 diabetes as an adjunct to insulin.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.